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OBJECTIVES: The aim of this manuscript is to describe the first year of our experience using extracorporeal
membrane oxygenation support.
METHODS: Ten patients with severe refractory hypoxemia, two with associated severe cardiovascular failure, were
supported using venous-venous extracorporeal membrane oxygenation (eight patients) or veno-arterial extra-
corporeal membrane oxygenation (two patients).
RESULTS: The median age of the patients was 31 yr (range 14–71 yr). Their median simplified acute physiological
score three (SAPS3) was 94 (range 84–118), and they had a median expected mortality of 95% (range 87–99%).
Community-acquired pneumonia was the most common diagnosis (50%), followed by P. jiroveci pneumonia in two
patients with AIDS (20%). Six patients were transferred from other ICUs during extracorporeal membrane
oxygenation support, three of whom were transferred between ICUs within the hospital (30%), two by ambulance
(20%) and one by helicopter (10%). Only one patient (10%) was anticoagulated with heparin throughout
extracorporeal membrane oxygenation support. Eighty percent of patients required continuous venous-venous
hemofiltration. Three patients (30%) developed persistent hypoxemia, which was corrected using higher positive
end-expiratory pressure, higher inspired oxygen fractions, recruitment maneuvers, and nitric oxide. The median
time on extracorporeal membrane oxygenation support was five (range 3–32) days. The median length of the
hospital stay was 31 (range 3-97) days. Four patients (40%) survived to 60 days, and they were free from renal
replacement therapy and oxygen support.
CONCLUSIONS: The use of extracorporeal membrane oxygenation support in severely ill patients is possible in the
presence of a structured team. Efforts must be made to recognize the necessity of extracorporeal respiratory
support at an early stage and to prompt activation of the extracorporeal membrane oxygenation team.
KEYWORDS: Extracorporeal Membrane Oxygenation; Respiratory Failure; Mechanical Ventilation; Patient Care
Team; Intensive Care Unit.
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INTRODUCTION
Since the first successful description of extracorporeal
membrane oxygenation (ECMO) in 1971 (1), this modality of
respiratory support has been investigated in several trials.
In 1979, the first randomized trial of ECMO in acute
respiratory distress syndrome (ARDS) patients resulted in
nonsignificant differences in mortality between the control
and ECMO groups (2). In 1986, Gattinoni et al. described,
with good outcomes, the use of ECMO to remove carbon
dioxide from the blood, enabling the use of low-frequency
mechanical ventilation, which was reported to have resulted
in a lower incidence of ventilation-associated lung injury (3).
In 1994, Morris et al. conducted a randomized trial to test
the effectiveness of this strategy of carbon dioxide (CO2)
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removal associated with low-frequency ventilation com-
pared with conventional treatment (4). The trial was
stopped early due to futility. Mechanical ventilation with
suboptimal settings and high airway pressures in the CO2
removal arm may have been associated with the negative
final result. In 2009, the CESAR trial demonstrated a
reduction in mortality and disability at six months among
severe ARDS patients using a combined strategy of ECMO
and protective mechanical ventilation compared with
conventional protective mechanical ventilation (5).
The renewed interest in the use of ECMO was also
fostered by the 2009 epidemic of severe pneumonia due to
influenza-A H1N1(6-13). Young patients with refractory
hypoxemia were common among those affected by this
disease, and respiratory rescue with ECMO was carried out
with excellent outcomes in Australia (14), the United
Kingdom (15), and Italy (16). These data suggest a survival
benefit of using ECMO in addition to conventional support
(15). In Brazil, many patients with influenza-A H1N1
required mechanical ventilation (17), and some of them
developed severe hypoxemia, in whom the case mortality
reached 11.6% (11). The absence of centers in Brazil that
specialize in ECMO limited the availability of adequate
support for those patients (18).
We implemented an ECMO service in two hospitals in
Sa˜o Paulo, Brazil. We followed a stepwise approach, which
included theoretical training of ECMO, the use of wet lab
practice with ECMO in animals in the research facility, and
finally the use of ECMO in patients at the bedside. The aim
of this manuscript is to describe the first year of our
experience using ECMO support in patients with severe
hypoxemic respiratory failure.
METHODS
The ECMO group comprised nurses, respiratory thera-
pists, and physicians. The care for ECMO-supported
patients was delivered by one physician, one nurse, two
nursing assistants, and one respiratory therapist, all of
whom were also in charge of three additional critically-ill
patients (19).
ECMO support was indicated based on individual
judgment of the following objective criteria (20):
Major criteria (both required):
- Acute or acute-on-chronic pulmonary disease
- Possibility of disease reversion
Complementary criteria (at least one required):
- P/F ratio#50 with FiO2= 1 for at least 1 hour, with or
without rescue maneuvers
- P/F ratio#50 with FiO2$0.8 for at least 3 hours, despite
rescue maneuvers
- Hypercapnia with pH#7.2 using a respiratory rate of at
least 35 breaths per minute, with a tidal volume of 4–
6 mL/kg of ideal body weight and a plateau
pressure#30 cmH2O
- Murray’s score (lung injury score).3.0 with the patient
presenting a clinical deterioration
ECMO support was not administered to patients with
severe chronic illness without the possibility of improve-
ment of their quality of life.
The canulation of patients was performed percutaneously
at the bedside with the Seldinger technique using femoral
and jugular canulae (Edwards Lifesciences, Irvine, CA,
EUA). In the three patients who were transferred from other
hospitals, we initiated the ECMO support before the patient
was transported. We primed the ECMO circuit with 600 mL
of normal saline solution at room temperature. A centrifugal
magnetic pump with a polymethylpentene oxygenation
membrane (Rotaflow/Jostra Quadrox - D, Maquet Cardio-
pulmonary AG, Hirrlingen, Germany) was used for all
patients.
Initially, the blood flow was maintained at 500 mL per
minute until the systemwas filled with blood. Blood flow and
sweep (gas) flow were subsequently increased to 2000 mL per
minute when using the venous-venous (VV) configuration.
The blood flow and sweep flow were then elevated in a 1:1
ratio, with a peripheral oxygen saturation target of at least
90%. When using the veno-arterial (VA) configuration, the
blood flow was gradually elevated to 5000 mL per minute,
and the sweep flow was set at 5 L per minute. The ECMO
support settings were adjusted based on the arterial blood
gases (in the VV configuration) or on the arterial blood
pressure, vasopressor requirement, and serum lactate levels
(in the VA configuration).
No prophylactic antibiotics were administered. Anticoa-
gulation with heparin was initiated at the team’s discretion,
beginning with 1000 IU per hour without bolus and
adjusted to reach an activated partial thromboplastin time
ratio of 1.5–2.5.
Mechanical ventilation was adjusted to a positive end-
expiratory pressure (PEEP) of 10-15 cmH2O, an inspired
fraction of oxygen (FiO2) of 0.3 or the least possible value, a
driving pressure of less than 10 cmH2O, and, if necessary, a
respiratory rate of 10 breaths per minute (5). The parameters
checked daily included arterial blood gases, clots in the
system visible through transillumination, pump campanula
auscultation, and flowmeter lubrication to maintain a good
signal quality. The ECMO blood flow was adjusted to
maintain a PaO2 greater than 55 mmHg, and the sweep flow
was adjusted to keep the pH$7.3 (through the PaCO2
modulation). Typical sedatives and analgesics were used if
necessary to reach a Richmond agitation sedation scale
(RASS) score of zero with no pain. Body temperature was
kept between 36 and 37 degrees Celsius with an external
apparatus adapted to the ECMO system.
A test to evaluate whether a patient could be weaned
from ECMO support was carried out daily. The mechanical
ventilation settings remained constant in patients with
pressure support ventilation; in patients under controlled
ventilation, the tidal volume was raised to 6 mL/ideal body
weight or was maintained at a level sufficient to keep the
plateau pressure ,25 cmH2O and the driving pressure
,15 cmH2O. In both situations, the FiO2 was set to 0.6. In
the VV configuration, the test consisted of stopping the
sweep flow. In the VA configuration, the test consisted of
reducing both the blood flow and sweep flow to 1,000 mL
per minute, with an ECMO FiO2 of 0.21. The weaning test
was interrupted if the patient presented a mean arterial
blood pressure ,65 mmHg, peripheral oxygen saturation
,85%, or respiratory distress (respiratory rate.35 breaths
per minute, accessory muscle use, abdominal muscle
contraction, diaphoresis, hypertension, or intense com-
plaints of dyspnea). After 1 hour, the patient was consid-
ered able to have the ECMO support removed (positive
ECMO support in severely ill patients
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weaning test) if he or she was hemodynamically stable
without elevations in inotropics or vasopressors, without
respiratory distress, with a PaO2$55 mmHg and a
pH$7.30. The decanulation was performed at the bedside
in the venous-venous configuration after the reversal of
anticoagulation. In the veno-arterial configuration, the
arterial canulae withdrawal was performed in the surgical
room.
Data are presented as medians (minimum–maximum),
which were obtained using the R – free source statistical
package (Vienna, Austria, 2009) (21).
RESULTS
During a one-year period, ten patients with severe
respiratory and/or cardiac dysfunction were supported
with ECMO. The general characteristics of patients are
shown in Table 1. The patients were young and had
extremely severe disease, as demonstrated by their high
expected mortality rate (Table 1). The most common
etiology of the acute cardiopulmonary dysfunction was
community-acquired pneumonia, and six of the ten patients
were transferred from outside ICUs.
The patients’ support and clinical statuses prior to ECMO
are shown in Table 2. They had low partial pressure of
oxygen to inspired fraction of oxygen (P/F) ratios, as well as
elevated PEEP and plateau pressures. At least one rescue
therapy strategy for refractory hypoxemia had been
performed on each patient prior to the initiation of ECMO.
We used five sets of 20 French canulae (five long venous
and five short arterial canulae) and five sets of 22 French
canulae to administer ECMO.
Data regarding the monitoring and physiological vari-
ables associated with ECMO support are shown in Tables 3
and 4. ECMO support enabled a significant reduction in
tidal volume and FiO2 during its use.
Table 5 presents the patient complications identified
during ECMO support. Pneumothorax, thrombocytopenia,
and hypoxic hepatitis were common complications of the
procedure, and there were no significant vascular complica-
tions in our patients.
Regarding the weaning tests, our patients were supported
by ECMO for a total of 92 days, during which time 89
autonomy tests were performed; nine tests were performed
in patients with the VA configuration, and 80 tests were
performed in patients with the VV configuration. Ten tests
were compatible with the removal of ECMO support;
however, in two tests (both in the venous-venous configura-
tion), at the discretion of the team, the patient wasmaintained
on ECMO support for one additional day. Seven tests failed
due to hypotension in patients using the veno-arterial
Table 1 - Characteristics of patients supported by ECMO.
General Characteristics (n = 10)
Age – yr 31 (14–71)
Gender – M/F – n (%) 5 (50)/5 (50)
Weight – kg 59 (46–84)
Pre-ECMO LOS – days * 9 (1–40)
SAPS 3 score # 94 (84–118)
Expected mortality – (%) 95 (87–99)
Duration of pre-ECMO hypoxemia (h) 9 (2–20)
Etiologic diagnosis
Community-acquired pneumonia 5 (50)
P. jiroveci pneumonia+AIDS 1 2 (20)
Alveolar hemorrhage+SLE " 1 (10)
Traumatic pulmonary contusion 1 (10)
Nosocomial pneumonia 1 (10)
Comorbidities
Hypertension 2 (20)
Diabetes 1 (10)
Heart failure 1 (10)
Atrial fibrillation 1 (10)
Transfer
No transfer 4 (40)
By in-hospital transportation 3 (30)
By ambulance 2 (20)
By helicopter 1 (10)
Quantitative data are shown as medians (minimum, maximum).
*ECMO denotes extracorporeal membrane oxygenation LOS denotes
length of stay.
# SAPS denotes simplified acute physiological score.
1AIDS denotes acquired immunodeficiency syndrome.
" SLE denotes systemic lupus erythematosus.
Table 2 - Pre-ECMO clinical status and support 1.
Arterial blood gases (n = 10)
PaO2 – mmHg 50 (36-56)
PaCO2 – mmHg 57 (31–142)
P/F ratio 50 (36-56)
Mechanical ventilation
PEEP – cmH2O 15 (10–23)
FiO2 1 (1–1)
Respiratory rate – breaths/minute 28 (18–90)
Tidal volume – mL 275 (130–400)
Plateau pressure – cmH2O 31 (25–46)
Pre-ECMO respiratory rescue maneuvers
Alveolar recruitment – n (%) 7 (70)
Neuromuscular blockade – n (%) 6 (60)
Corticosteroids – n (%) 4 (40)
High frequency ventilation – n (%) * 3 (30)
Tracheal gas insufflation – n (%) 1 (10)
Hemodynamics
Norepinephrine – n (%)/dosage
(mcg/kg/minute)
10 (100)/0.64 (0.28– 5.12)
Epinephrine – n (%)/dosage
(mcg/kg/minute)
2 (20)/0.44 (0.19–0.70)
Dobutamine – n (%)/dosage
(mcg/kg/minute)
3 (30)/15 (4-20)
Vasopressin – n (%)/dosage
(mcg/minute)
1 (10)/0.03
Mean arterial blood pressure – mmHg 63 (30–94)
Heart rate – beats/minute 145 (109-180)
Metabolic
Temperature - C˚ 37.4 (36.6–41.2)
Lactate – mEq/L 2.8 (1.6–4.1)
pH 7.17 (6.9–7.41)
SBE – mEq/L # -2.3 (-21.9–5.6)
Sedation, analgesia and
neuromuscular blockers
SAS 1.5 (1.0–3.0)
Midazolam - n (%)/dosage (mg/kg/hour) 4 (40)/0.16 (0.11–0.42)
Propofol - n (%)/dosage (mg/kg/hour) 4 (40)/0.73 (0.21–1.69)
Fentanyl - n (%)/dosage (mcg/kg/hour) 7 (70)/2.25 (0.85–6.28)
Thionembutal - n (%)/dosage
(mg/kg/hour)
1 (10)/3
Atracurium - n (%)/dosage (mg) 5 (50)/50 (50–50)
Cisatracurium - n (%)/dosage (mg) 1 (10)/20
All quantitative data are presented as medians (minimum, maximum).
1ECMO denotes extracorporeal membrane oxygenation.
*High-frequency ventilation denotes high-frequency positive pressure
ventilation (HFPPV).
# SBE denotes standard base excess.
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configuration, and 73 tests failed due to a peripheral
saturation,85% associated with respiratory distress.
Seven patients were ventilated with pressure support
during the positive weaning test, with a respiratory rate of
25 (20-42) breaths per minute, tidal volume of 310 (290-500)
mL, and PEEP of 8 (5-15) cmH2O. Analysis of the arterial
blood gases after one hour into the weaning test revealed a
pH of 7.392 (7.320-7.474), PaO2 of 81 (56-197) mmHg, PaCO2
of 41 (37-55) mmHg and SBE of 0.7 (-4–5.2) mEq/L.
Table 6 shows the clinical outcomes of the ten patients.
The median time of ECMO support was five days. The
majority of the patients were successfully weaned from
ECMO, and four patients survived to 60 days after hospital
discharge.
DISCUSSION
In these severely injured patients with an expected
survival of less than 13%, this study demonstrated a
survival of 40% when using ECMO for respiratory and/or
cardiovascular support. Another interesting aspect of this
study was the enrollment of patients with acquired
immunodeficiency syndrome (AIDS), who are not candi-
dates for ECMO support in classical ECMO referral centers
due to their high morbidity and mortality rates (22). Of note,
the two AIDS patients included in our study died; one death
was due to meningitis and the other was due to severe liver
failure, and both occurred after the removal of ECMO
support. One of these AIDS patients required 32 days of
ECMO support and died 11 days after ECMO weaning.
However, AIDS is a common condition among the patients
in the Brazilian public health care services (23), and the use
of ECMO support for those patients cannot be denied a
priori until it is evaluated in a prospective trial.
The high SOFA and simplified acute physiological score
(SAPS) 3 scores at the beginning of ECMO support in our
patients suggest late enrollment and late initiation of ECMO
support. This issue could be corrected by the early
recognition of severe ARDS and the early activation of the
ECMO team. To this end, promoting the awareness of the
methodology and the existence of a referral center within
the local medical community is likely an important step.
The VV configuration has lower oxygen-transfer efficacy
compared with the VA configuration due to recirculation
(24). Therefore, one can expect to have patients with
persistent hypoxemia during the administration of VV
ECMO support, as occurred in three of our patients. The
presence of pneumothorax was diagnosed at the time of
ECMO support weaning (data not published). We postulate
that these pneumothoraxes were the result of barotrauma
caused by the increase in transpulmonary pressure neces-
sary to maintain alveolar ventilation.
Central nervous system injury during ECMO support is
very common (25). Among the patients in our study, it is
interesting to note that two experienced a seizure; one
occurred during the system pause for lubrification of the
Table 3 - Respiratory and hemodynamic support and monitoring during extracorporeal membrane oxygenation.
Clinical characteristics First day Throughout support Last day
Lung injury score 3.00 (2.25–4.00) 3.00 (1.00–4.00) 2.00 (1.00–4.00)
Sequential organ failure assessment (SOFA) 18 (16–19) 14 (4–19) 14 (4–18)
ECMO support ¥
ECMO configuration – VV/VA – n (%) £ VV - 8 (80)/VA - 2 (20) VV - 8 (80)/VA - 2 (20) VV - 8 (80)/VA–2 (20)
Blood flow – mL/min 4500 (2300–6400) 4500 (600–7000) 4000 (1000–6000)
Sweep flow – L/min 5.5 (3.0–10.0) 3.0 (0.2–10.0) 2.0 (0.2–8.0)
Pump rotations - RPM 3885 (2400–4855) 4000 (1500–5560) 3000 (1500–5560)
FiO2 1.00 (0.40–1.00) 1.00 (0.40–1.00) 1.00 (0.40–1.00)
Ventilatory support
Patients on mechanical ventilation – n (%) 10 (100) 10 (100) 9 (90)
Pressure control ventilatory mode – n (%) 5 (50) 2 (20) 2 (20)
Pressure support ventilatory mode – n (%) 3 (30) 9 (90) 7 (70)
Bilevel ventilatory mode – n (%) 1 (10) 1 (10) 0 (0)
Volume control ventilatory mode – n (%) 1 (10) 1 (10) 0 (0)
PEEP – cmH2O 12 (10–18) 13 (6–20) 10 (6–15)
FiO2 0.30 (0.30–0.60) 0.30 (0.21–0.80) 0.30 (0.21–0.60)
Respiratory rate – breaths/min 18 (10–32) 23 (9–65) 20 (10–44)
Expiratory tidal volume - mL 150 (50–380) 185 (50–600) 260 (92–610)
PaO2 – mmHg 68 (49–126) 66 (43–126) 70 (50–126)
PaCO2 - mmHg 39 (21–51) 47 (21–77) 43 (23–64)
Respiratory rescue maneuvers
Nitric oxide – n (%) 2 (20) 2 (20) 1 (10)
Alveolar recruitment – n (%) 2 (20) 2 (20) 0 (0)
Hemodynamic support
Dobutamine – n (%)/mcg/kg/min * 6 (60)/15.0 (3.4–20.0) 5 (50)/10.0 (3.4–20) 3 (30)/20 (10–20)
Epinephrine – n (%)/mcg/kg/min * 4 (40)/0.28 (0.14–0.77) 4 (40)/0.23 (0.04–0.77) 2 (20)/0.06 (0.04–0.08)
Norepinephrine – n (%)/mcg/kg/min * 10 (100)/0.65 (0.04–2.82) 10 (100)/0.17 (0.02–2.82) 4 (40)/0.06 (0.04–1.75)
Vasopressin – n (%)/mcg/min * 2 (20)/0.04 (0.03–0.04) 4 (40)/0.03 (0.01–0.03) 2 (20)/0.04 (0.03–0.04)
Nitroprusside – n (%)/mcg/min * 0 (0) 0 (0) 1 (0)/0.5
Mean arterial blood pressure – mmHg 71 (30–120) 88 (30–126) 75 (60–126)
*This is the maximum dosage administered during the analyzed period when on drug use.
# This is the median dosage during the analyzed period when on drug use.
£ VV and VA denote the venous-venous and veno-arterial ECMO configuration, respectively.
¥ ECMO denotes extracorporeal membrane oxygenation.
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blood flowmeter, and the other occurred due to meningitis.
Three patients underwent brain death; one case was due to a
trauma-related carotid dissection, one was due to meningi-
tis and one was due to severe and prolonged hypoxemia
(,12 h) prior to ECMO administration. The former patient-
also developed severe hypoxia-related rhabdomyolysis and
hypoxic hepatitis, and he was the only patient who was
determined to be brain dead while receiving ECMO
support, which is a challenging diagnosis (26).
Sixty percent of our patients were transported from an
ICU to our referral ICUs, and all of them had ECMO
support initiated in loco. The transportation of ECMO-
supported patients with good results and survival has been
described previously (27,28). Three out of six of our patients
survived. It thus appears that the transportation of patients
during ECMO support is feasible in our service.
Another important point to discuss is the ECMO team. All
members were trained to perform the canulation at the
bedside using the Seldinger technique, and the team was
also the staff responsible for the care of the patients in the
ICU. There was no particular staff member designated
exclusively for the care of the ECMO-supported patients,
which is a staff configuration that can potentially reduce the
costs of ECMO support.
Our patients were allowed to awaken after the ECMO
installation and transport. Their comfort was maintained
despite their severe lung injuries. Some patients presented
respiratory compliances as low as 6 mL/cmH2O; however,
when the membrane sweep flow was sufficiently high, those
patients were usually comfortable while alert and oriented.
Only one patient was anticoagulated during the entire
ECMO support. The coexistence of bleeding or severe
coagulopathy in the remaining patients resulted in the
contraindication of anticoagulation (22). The new ECMO
systems have a heparin-bound surface, which allows the
ECMO support to proceed with minimal or no antic-
oagulation (29). In addition to the surface technology, the
use of a high blood flow through the system is likely
associated with the preservation of the ECMO circuits.
Renal replacement therapy is frequently applied through
the ECMO circuit (30). Eighty percent of our patients
required continuous venous-venous hemofiltration, which
was applied through an individual catheter, a choice we
made to minimize manipulations of the ECMO system.
Table 4 - Hematological, metabolic, infection and sedation support and monitoring of patients during extracorporeal
membrane oxygenation.
Hematological support First day Throughout support Last day
Hemoglobin – g/dL 7.6 (4.7–11.5) 7.5 (4.7–11.5) 7.0 (6.0–8.5)
Platelet count – platelets/mm3 120000 (41000–400000) 84000 (7000–40000) 67000 (19000–254000)
Patients on heparin therapy – n (%) 5 (50) 6 (60) 3 (30)
Heparin dosage – (IU/h) 1000 (500–1000) 1000 (500–1200) 1000 (500–1000)
APTT ratio " 1.7 (0.8–3.0) 1.3 (0.8–3.3) 2.1 (1.9–2.1)
International normalized ratio 1.5 (1.3–4.0) 1.3 (1.1–4.4) 1.4 (1.1–3.0)
Lactate dehydrogenase 1882 (1111–16173) 2281 (491–31413) 2175 (1322–31143)
Indirect bilirubin – mg/dL 0.23 (0.01–2.27) 0.29 (0.01–3.10) 0.38 (0.10–1.38)
Packed red cell transfusion – n (%)/units/patient 1 (10)/2 4 (40)/4 (3–11) 1 (10)/2
Plasma transfusion – n (%)/units/patient 0 (0)/0 3 (30) 1 (10)
Platelet transfusion – n (%)/units/patient 0 (0)/0 6 (60) 1 (10)
Metabolic support
Enteral energy intake – kCal 0 (0–475) 825 (0–1200) 638 (0–1200)
Enteral protein intake - g 0 (0–19) 36 (0–48) 26 (0–48)
Temperature - C˚ 36.4 (35.0–41.2) 36.4 (33.1–41.2) 36.2 (34.2–37.9)
pH 7.38 (7.11–7.51) 7.39 (7.11–7.51) 7.37 (7.29–7.47)
SBE – mEq/L 1 -5.0 (-18.9–8.4) 4.4 (-18.9–17) 1.6 (-13.3–11.1)
Serum lactate – mEq/L 4.4 (1.1–17.3) 3.1 (0.8–19.7) 2 (1.2–17.0)
Renal replacement therapy administration – n (%) 7 (70) 8 (80) 7 (70)
Renal replacement therapy mode – n (%) CVVHD 1(10)/CVVHF 6 (60) H CVVHF 8 (80) H CVVHF 7 (70) H
Adenosine citrate dextrose (ACD-A 2.2%)
administration – n (%)
2 (20) 5 (50) 5 (50)
Fluid balance – mL 1203 (-1028–7564) 428 (-4997–8612) 200 (-1355–3037)
Infection support
Patients using antibiotics – n (%) 9 (90) 10 (100) 9 (90)
C-reactive protein – mg/dL 177 (43–465) 165 (8–465) 167 (40–336)
Leukocytes – leuckocytes/mm3 13620 (2510–60350) 13620 (2510–60350) 11995 (7000–41980)
Sedation
SAS J 2 (1–5) 4 (1–6) 3 (1–4)
Patients receiving sedatives/analgesics – n (%) 9 (90) 9 (90) 5 (50)
Fentanyl – n (%)/mcg/kg/h # 8 (80)/1.1 (0.4–6.3) 8 (80)/1.0 (0.3–6.3) 5 (50)/0.8 (0.3–2.3)
Propofol – n (%)/mg/kg/h # 3 (30)/0.8 (0.5–2.1) 3 (30)/0.9 (0.2–2.1) 0 (0)
Midazolam – n (%)/mg/kg/h # 1 (10)/0.08 1 (10)/0.10 0 (0)
Dexmedetomidine – n (%)/mcg/kg/h # 1 (10)/0.5 2 (20)/0.2 (0.2–0.5) 0 (0)
*This is the maximum dosage used during the analyzed period.
£ VV and VA denote the venous-venous and veno-arterial ECMO configuration, respectively.
# This is the median dosage during the analyzed period.
HCVVHF denotes continuous venous-venous hemofiltration, and CVVHD denotes continuous venous-venous hemodialysis.
¥ ECMO denotes extracorporeal membrane oxygenation.
" APTT denotes activated partial thromboplastin time.
1SBE denotes standard base excess.
J SAS denotes sedation agitation score.
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When oxygenation was improving and there was low
respiratory compliance, we sometimes decided to apply a
strategy of permissive hypercapnia to wean patients from
ECMO support early. In this situation, if the kidney is
normal, the elimination of chloride with metabolic compen-
sation is normally promptly conducted (31); however,
during continuous hemofiltration therapy, we occasionally
found it useful to reduce the chloride concentration in the
replacement fluid.
The use of ECMO support in severely ill patients in Brazil is
possible in the presence of a structured team. Efforts must be
made to recognize the necessity of extracorporeal respiratory
support at an early stage and to prompt activation of the
ECMO team.
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